China’s NHSA Receives Record 818 Drug Applications for 2026 National Reimbursement Drug List Adjustment
China’s National Healthcare Security Administration (NHSA) announced that the application period for the 2026 adjustment...
Simcere Pharmaceutical Secures NMPA Approval for SIM0689 Bispecific Antibody Targeting PD-1 and VEGF in Solid Tumors
Simcere Pharmaceutical Group (HKG: 2096) announced that SIM0689, a novel bispecific antibody (BsAb) targeting both...
Mabwell Bioscience Secures FDA Approval for 6MW5311 Bispecific Antibody Trial in Hematologic Malignancies
Mabwell (Shanghai) Bioscience Co., Ltd. (SHA: 688062) announced that the U.S. Food and Drug Administration...
Qingfeng Pharmaceutical Group Partners with TASCO PHARMA to Commercialize Anti-Tumor and CNS Medicines in Vietnam
Qingfeng Pharmaceutical Group announced a strategic commercialization cooperation agreement with Vietnam’s TASCO PHARMA for the...
Merck Secures NMPA Approval for Enflonsia (Clesrovimab) – First Single-Dose RSV Monoclonal Antibody in China
Merck & Co., Inc. (MSD, NYSE: MRK) announced that China’s National Medical Products Administration (NMPA)...
Junshi Biosciences Secures Global Exclusive Rights to CAS’s Tetravalent Recombinant Dengue Vaccine in Landmark Licensing Deal
Shanghai Junshi Biosciences Co., Ltd. (HKG: 1877, SHA: 688180), a China-based biopharmaceutical company, has struck...
Shouyao Holdings Secures NMPA Approval for Second-Generation ALK Inhibitor CT-707 as First-Line Treatment for ALK-Positive NSCLC
Shouyao Holdings (Beijing) Co., Ltd. (SHA: 688197), a Beijing-based pharmaceutical company, announced it has received...
Createrna’s MY008211A Becomes China’s First Home-Grown Oral CFB Inhibitor Approved for Paroxysmal Nocturnal Hemoglobinuria
Wuhan Createrna Science and Technology Co., Ltd., a China-based biopharmaceutical company, announced it has received...
China’s CDE Releases 107th Batch of Reference Preparations for Generic Drug Consistency Evaluation with 17 New Drugs Added
China’s Center for Drug Evaluation (CDE) has published the 107th batch of reference preparations for...
Takeda’s Zasocitinib Demonstrates Superior Efficacy Over Deucravacitinib in Phase III Psoriasis Trial with 35% PASI 100 Response Rate
Takeda Pharmaceutical Company Limited (TYO: 4502; NYSE: TAK) announced positive topline results from a Phase...
Kelun-Biotech Receives USD 89 Million Settlement Payment from Medilink Therapeutics Over ADC Pipeline Out-Licensing Dispute
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (HKG: 6990), a China-based biopharmaceutical company, announced it has received...
WuXi AppTec Files Federal Lawsuit Against U.S. Department of Defense Over Erroneous Inclusion on Chinese Military Companies List
WuXi AppTec Co., Ltd. (SHA: 603259, HKG: 2359), a leading China-based contract research organization (CRO),...
HJ Science Launches HK$1.11 Billion IPO on Hong Kong Exchange to Advance Clinical-Stage Pipeline in Autoimmune, Metabolic, and Oncology Therapies
HJ Science Co., Ltd., (HKG: 6132) a China-based clinical-stage biotechnology company, announced its proposed initial...
LongBio Pharma’s Anti-IgE Antibody LP-003 Meets Primary Endpoint in Phase III Seasonal Allergic Rhinitis Trial
LongBio Pharma (HKG: 1779), a China-based biomacromolecule drug developer, announced that the Phase III clinical...
Cascade Pharmaceuticals Secures RMB 318 Million Series D Financing to Advance Bile Acid Metabolism Pipeline
Cascade Pharmaceuticals, Inc., a Shanghai-based sino-foreign joint venture biotechnology company, has secured RMB 318 million...
Novartis’ Del-Brax Meets Primary Endpoints in FSHD Biomarker Study – Potential First Disease-Modifying Therapy for Rare Muscular Dystrophy
Novartis AG (NYSE: NVS) announced that the biomarker cohort of the FORTITUDE Phase I/II clinical...
QuantumPharm (XtalPi) Secures $400 Million AI-Driven Partnership for Best-in-Class GPCR-Targeting Oral Small-Molecule Drug
QuantumPharm Inc. (HKG: 2228), operating as XtalPi Inc., announced a strategic AI-powered collaboration with an...
Novartis Secures Fourth China Approval for Tafinlar-Mekinist Combo in BRAF V600E-Mutated Radioactive Iodine-Refractory Differentiated Thyroid Cancer
Novartis AG (NYSE: NVS) announced that China’s National Medical Products Administration (NMPA) has granted approval...
Yipinhong Pharmacy Receives NMPA Clearance for APH03571 Dual-Mechanism Therapy in FLT3-Mutated Relapsed/Refractory AML
Yipinhong Pharmacy Co., Ltd. (SHE: 300723) announced it has received Investigational New Drug (IND) clearance...
CSPC Pharmaceutical’s Phase III Trial of Anbenitamab-Docetaxel Combination Meets Primary Endpoint in First-Line HER2-Positive Advanced Breast Cancer
CSPC Pharmaceutical Group (HKG: 1093) announced that its Phase III clinical trial evaluating Ennituo (anbenitamab)...